Q-omics provides the consensus-scored SLURP1 profile across patient tissues and cancer cell-line models. SLURP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SLURP1 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, SLURP1 protein abundance shows 31,854 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, HNSC, and LSCC as cancer lineages where SLURP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLURP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLURP1 survival associations across molecular data types. SLURP1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLURP1 RNA expression–survival associations across cancer types. High SLURP1 expression shows unfavorable associations in BRCA, PAAD, SKCM, UCEC and GBM, but favorable associations in ACC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SLURP1 RNA expression.
This table summarizes SLURP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLURP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLURP1 shows lower tumor expression in HNSC and higher tumor expression in BRCA, LUSC, KIRC, UCEC and BLCA. The HNSC box plot shows higher SLURP1 RNA expression in normal versus tumor tissue (log2 FC = −3.835, t-test p < 0.001).
This table shows molecular features associated with SLURP1 in patient tissues and cancer cell lines. In patient samples, SLURP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLURP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
